Arcutis Biotherapeutics (NASDAQ: ARQT)
Arcutis Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Arcutis Biotherapeutics Company Info
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
News & Analysis
Why Shares of Arcutis Biotherapeutics Fell This Week
The company released phase 3 trial results for an atopic dermatitis cream.
Why Shares of Arcutis Biotherapeutics Jumped This Week
The stock got a push when a British medical journal posted trials information on the company's lead product.
Could 2023 Be a Breakout Year for This Pharma Stock?
A pending FDA review and promising clinical trial data brings blockbuster potential.
Is Now the Time to Bet on Arcutis Biotherapeutics?
Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?
Why Arcutis Biotherapeutics Stock Is Plunging Today
The company announced the pricing of a public offering of common stock.
How Did Last Week's IPOs Perform?
These four companies just made their debuts. Should they be on your radar?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.